Research & Development
FDA Grants Coordination Pharmaceuticals IND Approval for CPI-100, a Novel Antitumor Nanomedicine
8 October 2018 - - The US Food and Drug Administration has approved US-based biopharmaceutical company Coordination Pharmaceuticals, Inc.'s Investigational New Drug application to initiate a first-in-human Phase 1 clinical study of CPI-100 in patients with advanced tumors, the company said.

CPI-100 is a structurally optimal core-shell nanoparticles based on CPI's proprietary nanoscale coordination polymer platform technology to selectively deliver immunostimulatory chemotherapeutic combinations to tumors, providing a new approach to initiate and stimulate immune-mediated eradication of cancer cells using synergistic nanomedicines.

Coordination Pharmaceuticals is a privately held oncology drug development company that aims to address unmet medical needs and improve patient care.

Its NCP technology is in-licensed from the University of Chicago with worldwide rights in development and commercialisation.
Login
Username:

Password:


Related Headlines

Palatin awarded US FDA approval for Vyleesi (bremelanotide injection) NDA for HSDD in premenopausal women

ArQule Presents Preliminary Results from Its Phase 1/2 Study of Miransertib in Patients with PIK3CA-related Overgrowth Spectrum and Proteus syndrome in an Oral Presentation at the European Society of Human Genetics Conference

Triumvira Immunologics IND and CTA Cleared by US FDA and Health Canada for Its First TAC T-cell Therapeutic Product Candidate, TAC01-CD19

FDA Approves US Merck's Keytruda as Monotherapy for Patients with Metastatic Small Cell Lung Cancer with Disease Progression on or After Platinum-Based Chemotherapy and at Least One Other Prior Line of Therapy

Lynparza Approved in the EU for Use as First-Line Maintenance Therapy in Patients With BRCA-Mutated Advanced Ovarian Cancer

Edesa Biotech to launch its US clinical study of EB01 following FDA approval

ANI Pharmaceuticals gains FDA approval for Vancomycin Hydrochloride for Oral Solution

Camurus gets FDA green light to launch phase 3 trial with CAM2029 for treatment of acromegaly

Novo Nordisk receives EU marketing authorisation for Esperoct

Resolution Liquid Biopsy Assay Detects More Complex Variants than Guardant360 in Retrospective Lung Cancer Comparison Study

New Article Published in Cancer CytopathologyDetailing Clinical Utility of Its RNA Sequencing-Based Testing for Thyroid Cancer Diagnosis and Treatment

Mycovia Pharmaceuticals and Jiangsu Hengrui Medicine Partner to Develop and Commercialise VT-1161 for Recurrent Vulvovaginal Candidiasis and Other Fungal Conditions

Dyne Therapeutics Supports END-DM1 Natural History Study of Patients with Myotonic Dystrophy Type 1

Xeris Pharmaceuticals Touts Additional Positive Outcomes from a Global Phase 3 Clinical Trial of Its Investigational Ready-to-Use Glucagon

Alnylam Completes Enrollment for ILLUMINATE-A Phase 3 Study of Lumasiran in Patients with Primary Hyperoxaluria Type 1